Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Irritable bowel syndrome symptom severity improves equally with probiotic and placebo

  • 2016
  • World Journal of Gastroenterology 22(48)
    • Anna Lyra
    • M. Hillilä
    • T. Huttunen
    • Sofia Männikkö
    • M. Taalikka
    • Julia Tennilä
    • A. Tarpila
    • S. Lahtinen
    • A. Ouwehand
    • L. Veijola

Abstract

Aim: To determine the effects of Lactobacillus acidophilus NCFM on irritable bowel syndrome (IBS) symptoms and quality of life (QoL).

Methods: In this randomized triple-blind trial, adult IBS volunteers who were recruited according to Rome III criteria received 109 or 1010 colony-forming units of NCFM or placebo daily for 12 wk. IBS Symptom Severity Score (IBS-SSS), which constituted the primary outcome, and secondary outcomes, including individual IBS symptoms, IBS-related QoL questionnaire, anxiety and depression, defecation frequency, and stool consistency, were assessed at baseline at the end of the 8-wk run-in period, after 4 and 12 wk of intervention, and after a 4-wk washout.

Results: A total of 340 of 391 randomized volunteers completed the trial. IBS-SSS improved over 12 wk of treatment in all treatment groups, decreasing by a mean ± SD of 44.0 ± 80.2, 50.8 ± 82.4, and 48.3 ± 72.2 in the placebo, active low-dose, and active high-dose groups, respectively. Similarly, secondary outcomes did not differ between treatment groups. However, in a post hoc analysis of volunteers with moderate to severe abdominal pain at baseline (VAS > 35/100), the treatment significantly reduced the sensation of abdominal pain. Pain scores fell by 20.8 ± 22.8, 29.4 ± 17.9, and 31.2 ± 21.9 in the placebo, active low-dose, and active high-dose groups, respectively (P value for placebo vs combined active doses = 0.0460).

Conclusion: NCFM alleviates moderate to severe abdominal pain, consistent with earlier observations of this strain mitigating visceral pain through increased analgesic receptor expression.

Keywords: Abdominal pain; Functional bowel disorder; Intervention; Irritable bowel syndrome; Lactobacillus acidophilus; Probiotic; Quality of life; Symptom questionnaire; Visceral pain.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus acidophilus NCFMImproved Irritable Bowel Syndrome Symptom SeverityNeutral
Small
Lactobacillus acidophilus NCFMReduced Abdominal Pain SeverityBeneficial
Moderate
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.